6 February 2019 ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)
7 January 2019 ORYZON appoints Michael T. Ropacki, PhD as Vice President of Clinical Development for its CNS epigenetic program
11 December 2018 ORYZON receives a new 1.14 M USD public grant to explore new indications for epigenetic inhibitors
3 December 2018 Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients
12 November 2018 Oryzon announces First-Patient-in in ALICE: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Acute Myeloid Leukemia patients
2 November 2018 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018
26 October 2018 Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors